0001140361-17-044232.txt : 20171129
0001140361-17-044232.hdr.sgml : 20171129
20171129172138
ACCESSION NUMBER: 0001140361-17-044232
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171127
FILED AS OF DATE: 20171129
DATE AS OF CHANGE: 20171129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Van Naarden Jacob
CENTRAL INDEX KEY: 0001661254
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36562
FILM NUMBER: 171229333
MAIL ADDRESS:
STREET 1: C/O LOXO ONCOLOGY, INC.
STREET 2: ONE LANDMARK SQUARE, SUITE 1122
CITY: STAMFORD
STATE: CT
ZIP: 06901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Loxo Oncology, Inc.
CENTRAL INDEX KEY: 0001581720
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462996673
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06901
BUSINESS PHONE: 203-653-3880
MAIL ADDRESS:
STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06901
4
1
doc1.xml
FORM 4
X0306
4
2017-11-27
0
0001581720
Loxo Oncology, Inc.
LOXO
0001661254
Van Naarden Jacob
C/O LOXO ONCOLOGY, INC.
281 TRESSER BOULEVARD, 9TH FLOOR
STAMFORD
CT
06901
0
1
0
0
Chief Business Officer
Common Stock
2017-11-27
4
M
0
1541
3.648
A
1541
D
Common Stock
2017-11-27
4
S
0
841
74.0811
D
700
D
Common Stock
2017-11-27
4
S
0
400
74.9625
D
300
D
Common Stock
2017-11-27
4
S
0
300
76.7633
D
0
D
Common Stock
2017-11-28
4
M
0
1541
3.648
A
1541
D
Common Stock
2017-11-28
4
S
0
600
73.2683
D
941
D
Common Stock
2017-11-28
4
S
0
500
74.0340
D
441
D
Common Stock
2017-11-28
4
S
0
441
75.5187
D
0
D
Employee Stock Option (right to buy)
3.648
2017-11-27
4
M
0
1541
0
D
2024-06-18
Common Stock
1541
118166
D
Employee Stock Option (right to buy)
3.648
2017-11-28
4
M
0
1541
0
D
2024-06-18
Common Stock
1541
116625
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
Represents the aggregate of sales effected on the same day at different prices.
Represents the weighted average sales price per share. The shares sold at prices ranging from $73.56 to $74.44 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. The shares sold at prices ranging from $74.58 to $75.47 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. The shares sold at prices ranging from $76.11 to $77.09 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. The shares sold at prices ranging from $72.68 to $73.62 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. The shares sold at prices ranging from $73.74 to $74.28 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. The shares sold at prices ranging from $75.03 to $75.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
/s/ Jennifer Burstein, by power of attorney
2017-11-29